BioMerieux (XPAR:BIM) Other Gross PPE : €1,589 Mil (As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is BioMerieux Other Gross PPE?

BioMerieux's Other Gross PPE for the quarter that ended in Dec. 2023 was €1,589 Mil.

BioMerieux's quarterly Other Gross PPE increased from Dec. 2022 (€1,422 Mil) to Jun. 2023 (€1,503 Mil) and increased from Jun. 2023 (€1,503 Mil) to Dec. 2023 (€1,589 Mil).

BioMerieux's annual Other Gross PPE increased from Dec. 2021 (€1,321 Mil) to Dec. 2022 (€1,422 Mil) and increased from Dec. 2022 (€1,422 Mil) to Dec. 2023 (€1,589 Mil).

BioMerieux Other Gross PPE Historical Data

The historical data trend for BioMerieux's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioMerieux Other Gross PPE Chart

BioMerieux Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Gross PPE

Get a 7-Day Free Trial

1,143.50

1,161.10

1,321.30

1,422.00

1,588.70

BioMerieux Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Other Gross PPE	Get a 7-Day Free Trial															1,321.30	705.30	1,422.00	1,503.30	1,588.70

BioMerieux Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.

BioMerieux (XPAR:BIM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BioMerieux SA (XPAR:BIM) » Definitions » Other Gross PPE

Comparable Companies

Traded in Other Exchanges

BMXMF:USA BIMp:UK 0RUG:UK EYWN:Germany BIM:Austria

Address

Marcy l’Etoile, Lyon, FRA, 69280

Website

http://www.biomerieux.com

BioMerieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (38% of 2021 sales), microbiology (31%), immunoassays (14%), and industrial applications (about 17%). The Americas account for the largest portion of the firm's revenue (49%), followed by Europe, the Middle East, and Africa (33%), and Asia-Pacific (18%). BioMerieux is headquartered in Marcy-l'Etoile, France.

BioMerieux (XPAR:BIM) Headlines

No Headlines